Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Omega Therapeutics, Inc. (OMGA : NSDQ)

• Company Description    Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass. Number of Employees: 117

• Price / Volume Information    Yesterday's Closing Price: $7.20 Daily Weekly Monthly 20 Day Moving Average: 81,632 shares Shares Outstanding: 55.02 (millions) Market Capitalization: $396.17 (millions) Beta: 0.97 52 Week High: $11.98 52 Week Low: $2.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.67% -14.05% 12 Week 3.15% -4.25% Year To Date 26.09% 14.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 ACORN PARK DRIVE - CAMBRIDGE,MA 02140 USA ph: 617-949-4360 fax: - estroynowski@omegatx.com http://www.omegatherapeutics.com

• General Corporate Information    Officers Mahesh Karande - President; Chief Executive Officer and Director Noubar B. Afeyan - Chairman of the Board of Directors Joshua Reed - Chief Financial Officer Rainer Boehm - Director Luke M. Beshar - Director Peer Information Omega Therapeutics, Inc. (CORR.) Omega Therapeutics, Inc. (RSPI) Omega Therapeutics, Inc. (CGXP) Omega Therapeutics, Inc. (BGEN) Omega Therapeutics, Inc. (GTBP) Omega Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68217N105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/03/23 Share - Related Items Shares Outstanding: 55.02 Most Recent Split Date: (:1) Beta: 0.97 Market Capitalization: $396.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.22 Price/Cash Flow: - Price / Sales: 170.61 EPS Growth vs. Year Ago Period: -19.05% vs. Previous Quarter: 21.87% Sales Growth vs. Year Ago Period: 92.54% vs. Previous Quarter: -29.80% ROE 03/31/23 - -82.93 12/31/22 - -71.03 09/30/22 - -55.11 ROA 03/31/23 - -64.81 12/31/22 - -56.55 09/30/22 - -45.58 Current Ratio 03/31/23 - 8.22 12/31/22 - 6.26 09/30/22 - 10.96 Quick Ratio 03/31/23 - 8.22 12/31/22 - 6.26 09/30/22 - 10.96 Operating Margin 03/31/23 - -4,643.24 12/31/22 - -4,951.83 09/30/22 - -6,252.80 Net Margin 03/31/23 - -4,643.24 12/31/22 - -4,951.83 09/30/22 - -6,252.80 Pre-Tax Margin 03/31/23 - -4,643.24 12/31/22 - -4,954.22 09/30/22 - -6,253.54 Book Value 03/31/23 - 2.24 12/31/22 - 2.21 09/30/22 - 2.79 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.11 12/31/22 - 0.16 09/30/22 - 0.15 Debt-to-Capital 03/31/23 - 10.29 12/31/22 - 13.55 09/30/22 - 12.96

Powered by Zacks Investment Research ©